The SLC30A8 gene, which encodes the zinc transporter ZnT-8 that is expressed in pancreatic β-cells, is one of the earliest and most illustrative examples of the use of T2D-associated SNVs in anti-diabetic therapy. This evidence concerns the gene SLC30A8 and type 2 diabetes mellitus.